July 15, 2005= Boehringer Ingelheim
Pharmaceuticals, Inc. today announced an
agreement was reached between the company and the ADAP Crisis Task
Force,
convened by the National Alliance of State and Territorial AIDS
Directors, regarding
Aptivus (tipranavir),
the anti-HIV drug recently approved by the FDA.
Based on this agreement, Boehringer Ingelheim will work closely with
state
ADAPs to facilitate the inclusion of APTIVUS on ADAP formularies.
Viramune (nevirapine) will continue to be available for patients who
obtain their anti-HIV medications through ADAPs.
"This agreement reaffirms the commitment of Boehringer Ingelheim to
assure
that people who need our HIV medications will receive them," said Jim
Rowenhorst of Boehringer Ingelheim Pharmaceuticals, Inc.
"ADAPs across the country are struggling to provide life-saving
medications
with funding that does not keep pace with the growing demand for
services.
Boehringer Ingelheim's participation in this agreement will help in our
efforts to stabilize the program nationally," said Dwayne Haught, a
member
of NASTAD's ADAP Crisis Task Force.
This agreement marks an important step in broadened access for patients
to
APTIVUS and extended access to VIRAMUNE. |
Aptivus (Tipranavir) Access
to be Broadened through
AIDS Drug Assistances Programs
AIDS Drug Assistance Protocol Fund
New and Noteworthy
ADAP Main Page
|
